Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 30, 2015 12:30 PM ET

Healthcare Equipment and Supplies

Company Overview of MIV Therapeutics Inc.

Company Overview

MIV Therapeutics, Inc. engages in the research, development, and commercialization of biocompatible coatings for stents, and other medical devices and drug delivery systems. It offers products for providing healing solutions for cardiovascular disease and other medical conditions. The company’s pre-clinical development stage products include bare metal cardiovascular stents and drug-eluting cardiovascular stents. In collaboration with the University of British Columbia, the company developed coating technologies that utilize Hydroxyapatite for application on medical devices and drug delivery systems. The company is based in Vancouver, Canada.

8765 Ash Street

Unit 1

Vancouver, BC V6P 6T3

Canada

115 Employees

Phone:

604-301-9545

Fax:

604-301-9546

Key Executives for MIV Therapeutics Inc.

Chairman and Chief Executive Officer
Director of Investor Relations
Member of Medical Advisory Board and Clinical Advisor to MIVT India
Researcher
Compensation as of Fiscal Year 2014.

MIV Therapeutics Inc. Key Developments

SEC Orders Hearing On Registration Suspension Or Revocation Against MIV Therapeutics

In conjunction with the trading suspension, Securities and Exchange Commission (SEC or Commission) also instituted public administrative proceedings to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of MIV Therapeutics Inc. for failure to make required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceedings.

MIV Therapeutics Inc. Announces Executive Changes

MIV Therapeutics Inc. announced that the company accept the resignation of Mr. Chris Chen as director and officer while welcome its new leader, Chairman & CEO Mr. XIAO.

Similar Private Companies By Industry

Company Name Region
SCIREQ Scientific Respiratory Equipment Inc. Americas
Dentsply Canada Ltd. Americas
VisualSonics, Inc. Americas
Innovative Trauma Care Ltd. Americas
Metabolomic Technologies Inc. Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MIV Therapeutics Inc., please visit www.mivtherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.